13 – What did the PATHFINDER Study Reveal about Multi-Cancer Early Detection Testing?
Release Date: 10/31/2023
20 – Improving Cancer Screening in the LGBTQ+ Community
The Cancer SIGNAL
Jon Rendina and Dwight Venson of Whitman-Walker, a healthcare center historically focused on the LGBTQ+ community, join us to delve into how LGBTQ+ people and people of color face disparities in cancer incidence. Whitman-Walker, Cancer Support Community, and GRAIL are collaborating on INCLUDE, a study to evaluate multi-cancer early detection (MCED) testing’s impact within federally qualified health centers. The goal: make this kind of cancer screening available to more people in the future. Jon and Dwight discuss barriers to access, how LGTBQ+ and minority experiences of cancer care can be...
info_outline
19 – The Power of Diverse Representation in Clinical Trials
The Cancer SIGNAL
Diverse clinical trials provide more meaningful data to researchers, but too many trials are based around monolithic audience groups. In early disease detection, particularly in conditions like cancer, diversity in clinical trials is especially important. Our guests, Eucharia Borden of the cancer nonprofit Family Reach and Dr. Gary Puckrein of the National Minority Quality Forum, discuss why diversity in clinical trials is critical and how to foster inclusivity in clinical research, getting us closer to healthcare equity. Help shape future episodes by taking our survey: ...
info_outline
18 – When a Proactive Cancer Screening Leads to a Surprising Diagnosis
The Cancer SIGNAL
After supporting her husband through his shocking cancer experience, Cindy decided to take a multi-cancer early detection test as recommended by her doctor. She was once again shocked when she received a “cancer signal detected” result, leading to a cancer diagnosis. Join us to hear about Cindy’s experience with early detection, treatment, and eventual remission, and what she learned along the way. We want your feedback! Please take our podcast survey: Transcripts: Sign up for GRAIL’s newsletter:
info_outline
17 – Navigating Hereditary Cancer Risk – Part 2
The Cancer SIGNAL
Join host Kim Thiboldeaux and Krissa Smith, VP of Mission Partnerships at Susan G. Komen, as they continue unraveling how the BRCA gene and other DNA mutations impact hereditary cancer risk. In this episode, Krissa shares personal stories about her family's experiences with genetic testing and how they’ve chosen to respond. Krissa also discusses cancer screening best practices and how multi-cancer early detection testing can play a role. Please take our survey to help us shape future episodes: Transcripts: Sign up for GRAIL’s newsletter:
info_outline
16 – Understanding BRCA Mutations and Hereditary Cancer Risk – Part 1
The Cancer SIGNAL
Krissa Smith, Vice President of Mission Partnerships at Susan G. Komen, joins us to discuss the complexities of the BRCA gene and its impact on hereditary cancer risk. Krissa shares her family's experiences with genetic mutations, including the p53 gene, and explains the importance of genetic testing and how it can work in partnership with evolving cancer screening technology. Stay tuned for part 2 to learn more about genetics, cancer risk, and the importance of early detection. Please take our survey to help us shape future episodes: Transcripts: Sign up for GRAIL’s newsletter:
info_outline
15 – Meet Tami: Cancer Survivor Turned Advocate
The Cancer SIGNAL
Meet Tami, manager of a Christmas tree farm in rural Oregon. Cancer has had a profound impact on Tami’s life, from her grandmother's diagnosis more than 30 years ago to her own 2017 diagnosis to her participation in the PATHFINDER study. Tami shares what she’s learned about cancer and the importance of proactive screening, including her own experiences with multi-cancer early detection (MCED) testing. Please take our survey to help us shape future episodes: Transcripts: Sign up for GRAIL’s newsletter:
info_outline
14 – The COVID-19 Pandemic’s Impact on Cancer Screenings
The Cancer SIGNAL
In the years since the COVID-19 pandemic began, cancer screening has changed, necessitating inventive strategies. Epidemiologists Dr. Alpa Patel (Senior Vice President of Population Science, American Cancer Society) and Dr. Tina Clarke (Vice President of Epidemiology and Distinguished Scientist, GRAIL) return to The Cancer SIGNAL to discuss how the pandemic changed access to cancer screening, the impact it had on diagnosing cancer, and where that leaves the screening landscape today. Please take our survey to share your thoughts on The Cancer SIGNAL: Transcripts:...
info_outline
13 – What did the PATHFINDER Study Reveal about Multi-Cancer Early Detection Testing?
The Cancer SIGNAL
What did researchers learn when they studied a multi-cancer early detection test in a population of more than 6,000 patients? The PATHFINDER study, recently published in The Lancet, explored that question and produced useful insights. Dr. Chuck McDonnell, a radiologist with Sutter Medical Group and principal investigator for PATHFINDER, joins this episode to discuss how the study worked, highlights of the results, and what they could mean for the future of cancer screening. Transcripts available at Sign up for GRAIL’s newsletter:
info_outline
12 – Improving Cancer Screening and Care in Native American Communities
The Cancer SIGNAL
The American Indian Cancer Foundation is on a mission to eliminate the cancer burdens of Indigenous people through improved access to prevention, early detection, treatment and survivor support. Melissa Buffalo, CEO of the Foundation, discusses the cancer burden faced by Native Americans and what her Foundation is doing to reduce disparities in care. Transcripts available at Sign up for GRAIL’s newsletter:
info_outline
11 – Roger’s Story: Detecting Pancreatic Cancer in its Early Stages
The Cancer SIGNAL
When Roger received a confirmed diagnosis of pancreatic cancer, an aggressive, fast-growing and often deadly cancer, one doctor called him “lucky,” since Roger’s cancer was found at an early stage and before he showed any symptoms. Roger had been screened with a multi-cancer early detection test as part of his efforts to take care of his health. Learn more about Roger’s story and hear how he is doing today. Transcripts available at Sign up for GRAIL’s newsletter:
info_outlineWhat did researchers learn when they studied a multi-cancer early detection test in a population of more than 6,000 patients? The PATHFINDER study, recently published in The Lancet, explored that question and produced useful insights. Dr. Chuck McDonnell, a radiologist with Sutter Medical Group and principal investigator for PATHFINDER, joins this episode to discuss how the study worked, highlights of the results, and what they could mean for the future of cancer screening.
Transcripts available at https://grail.com/podcast/
Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/